Castration-resistant prostate cancer cells treated with metformin and simvastatin were shown to induce Ripk1- and Ripk3-dependent necrosis, suggesting that these necroptosis molecules may be important in the antitumor effects mediated by metformin [42]. This evidence concerns the gene RIPK1 and prostate carcinoma.